Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Financing innovation programme
      • Digital library
      • Data desk
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Financing innovation programme
        • Go back
        • Overview
        • Our studies on the financing of innovation
        • EPO initiatives for patent applicants
        • Financial support for innovators in Europe
      • Digital library
      • Data desk
        • Go back
        • Overview
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1915/10 (Immunogenic composition/vaccine of at least two S. pneumoniae proteins/GlaxoSmithKline) 02-10-2014
Facebook X Linkedin Email

T 1915/10 (Immunogenic composition/vaccine of at least two S. pneumoniae proteins/GlaxoSmithKline) 02-10-2014

European Case Law Identifier
ECLI:EP:BA:2014:T191510.20141002
Date of decision
02 October 2014
Case number
T 1915/10
Petition for review of
-
Application number
01984627.8
IPC class
A61K 39/09
A61P 31/04
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 370.84 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Vaccine against streptococcus pneumoniae

Applicant name
GlaxoSmithKline Biologicals s.a.
Opponent name
-
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 56
Keywords
Inventive step - (yes)
Catchword
-
Cited decisions
T 0939/92
T 0964/92
T 0350/95
T 0716/08
Citing decisions
T 2923/18

I. This appeal was lodged by the applicant (hereinafter "appellant") against the decision of the examining division to refuse the European patent application

No. 01984627.8, published as international application WO 02/22168. The title of the application is "Vaccine against Streptococcus pneumoniae".

II. The following documents are referred to in this decision:

(D1) Ogunniyi A. D. et al; Infection and Immunity, 2000; 68(5): 3028-3033

(D2) WO 00/37105

(D5) Jedrzejas M. J.; Microbiology and Molecular Biology Reviews, 2001; 65(2): 187-207

(D6) Post-published technical data filed as point 4.2.2 of the statement of grounds of appeal concerning (i) the protection induced by immunisation with Ply and PhtD and (ii) data of a clinical trial testing the immunogenicity of different Ply and/or PhtD formulations in adults.

III. The decision under appeal was based on a main, first and second auxiliary request filed during the written proceedings and a third auxiliary request filed during the oral proceedings. The examining division found that the subject-matter of claim 1 of the main and first auxiliary request lacked novelty (Article 54 EPC) and that the subject-matter of claim 13 of the second auxiliary request lacked clarity (Article 84 EPC). In relation to the third auxiliary request the examining division decided not to admit post-published "supplementary technical information" and that the subject-matter of claim 1 did not involve an inventive step (Article 56 EPC).

(i) The examining division assessed the admissibility of the "supplementary technical information" (which corresponds to the data of document D6 in the appeal proceedings) as follows:

The information filed on 16 August 2006 concerned post-published data about the protection induced by the immunisation of mice with Ply and PhtD. Additional post-published data filed on 25 September 2009 concerned a clinical trial testing the immunogenicity of different Ply and/or PhtD formulations in adults. According to the examining division these data were provided by the appellant to show that the immunogenic composition of PhtD and Ply "represents a vaccine generating an unexpectedly good protective effect".

In the examining division's opinion neither the experimental data provided in the application as filed nor the common general knowledge represented by the prior art document (D1) provided a basis for the skilled person to conclude plausibly that the specific combination of the claimed S. pneumoniae antigens PhtD and Ply represented a solution to the technical problem of providing a vaccine against S. pneumoniae (note added by the board: as claimed in claim 10 of the third auxiliary request). The application as filed merely disclosed that native Ply and PhtD were immunogenic but a protective effect of a combination of these proteins as required for a vaccine was not shown. Moreover, document (D1) disclosing the general understanding of pneumococcal protein vaccines at the date of filing of the present application showed that an immunogenicity per se of protein compositions comprising Ply together with one or two further virulence factors was not a sufficient prerequisite for such a composition to consistently induce a protective response as required for a vaccine. The "supplementary technical information" was therefore not admitted.

(ii) Regarding the lack of inventive step of the subject-matter of

claim 1 the examining division reasoned as follows:

Document (D1) was the closest prior art for the subject-matter of claim 1. It disclosed a study of detoxified Ply and the two pneumococcal virulence factors PsaA and PspA in different immunogenic combinations. The application as filed did not disclose data that supported the presence of an improved immunogenic property of the claimed combination of PhtD and detoxified Ply over the immunogenic combinations known from document (D1).

The objective technical problem to be solved in view of document (D1) was therefore the provision of an alternative immunogenic composition. According to the subject-matter of claim 1 this problem was solved by an immunogenic composition comprising at least PhtD and Ply. That this subject-matter solved the underlying technical problem was credible because the application as filed provided evidence that a composition comprising native Ply and PhtD induced Ply- and PhtD-specific antibodies.

The examining division considered this solution obvious. The skilled person looking for alternatives would combine Ply of document (D1) with other known immunogenic pneumococcal proteins suitable for vaccine development. It would therefore turn to document (D2) disclosing such proteins, inter alia PhtD. The combination of Ply and PhtD was the result of "an arbitrary selection among the solutions that can be generated on the basis of the disclosure of the antigenic proteins of both D1 and D2. Such an arbitrary selection, however, fails to represent a contribution to the prior art for which an inventive step can be acknowledged". The skilled person would thus have arrived in an obvious manner at the subject-matter of claim 1.

IV. With its statement of grounds of appeal the appellant filed a main request and a first auxiliary request which was identical to the third auxiliary request before the examining division, and documents (D5) and (D6). It requested that the decision under appeal be set aside and that a patent be granted on the basis of either the main or the auxiliary request. On an auxiliary basis, oral proceedings were requested.

V. The appellant was summoned to oral proceedings scheduled for 25 June 2014.

VI. In a telephone conversation on 20 May 2014 the rapporteur informed the appellant of the board's view that the auxiliary request but not the main request was allowable. The appellant then withdrew its main request and requested the "continuation of the examination on the basis of auxiliary request 1 filed on 28 May 2010", i.e. the appellant requested that the decision under appeal be set aside and that a patent be granted on the basis of auxiliary request 1 filed with the statement of grounds of appeal.

Claims 1 and 10 to 13 of auxiliary request 1 read:

"1. An immunogenic composition comprising at least 2

S. pneumoniae proteins wherein one of the proteins is PhtD and another protein is detoxified pneumolysin (Ply).

10. A vaccine comprising the immunogenic composition of claim 1-9.

11. Use of the vaccine of claim 10 in the manufacture of a medicament for prevention of pneumonia in patients over 55 years of age.

12. Use of the vaccine of claim 10 in the manufacture of a medicament for prevention of Otitis media in infants.

13. A method of making a vaccine as claimed in claim 10 comprising the steps of: selecting and isolating two different S. pneumonia proteins which are PhtD and detoxified pneumolysin (Ply); and mixing said proteins together with a pharmaceutically acceptable carrier."

VII. The board cancelled the oral proceedings.

VIII. The appellant's arguments, in so far as they are relevant for the present decision, may be summarized as follows:

Inventive step

Document (D1) was the closest prior art with regard to the subject-matter of claim 1, since it disclosed several immunogenic combinations of pneumococcal proteins suitable for vaccination, including detoxified Ply. The S. pneumoniae protein PhtD was not mentioned.

The problem to be solved in view of the closest prior art document (D1) was the provision of a further combination of S. pneumoniae proteins with improved immunogenicity.

The problem was solved by the subject-matter of

claim 1.

The application as filed established that it was plausible that a combination of pneumolysin and PhtD could generate a useful immune response. Example 2 showed that infants and adults developed antibodies against these two proteins upon exposure to a complete S. pneumoniae bacterium, i.e. a combination of all possible native pneumococcal antigens. A particularly strong response was induced against PhtD.

Moreover, the application disclosed on page 3, line 30 to page 4, line 3 that combinations of two proteins from different "categories" were preferred and explicitly indicated that the combination of PhtD and Ply in an immunogenic composition was preferred.

Decisions T 1329/04 and T 536/07 suggested that to reach the plausibility threshold all that was required was that there was no prejudice in the art against the solution put forward. This was so in the present case.

Document (D1) disclosed that all immunogenic combinations containing detoxified Ply provided some degree of protection (see table 2, page 3029, column 2, lines 30 to 32). Document (D2) described an active protection of mice after a vaccination with PhtD (see example 6).

Under these circumstances, the post-published data of document (D6) should be taken into account for the assessment of inventive step. These data showed that the combination of PhtD and Ply was more effective than each protein alone in inducing a protective response in mice challenged with S. pneumoniae, and that PhtD augmented the anti-Ply antibody immune response in human adults.

To arrive at the solution of claim 1 the skilled person would have to retain one of the proteins of the different combinations disclosed in document (D1) and combine it with one of the four proteins disclosed in document (D2). However, there was no hint derivable from any of the documents that would motivate the skilled person to select the particular protein combination as claimed. If anything, the skilled person would have combined the proteins disclosed in document (D1) with a further virulence factor such as that disclosed in document (D5). However, this document did not mention PhtD.

|

IX. The appellant requested that the decision under appeal be set aside and that a patent be granted on the basis of the auxiliary request 1 filed with the statement of grounds of appeal.|

1. The claims of the sole request before the board are the same as those of the third auxiliary request dealt with in the decision under appeal. Claims 1, 10 and 13 are independent claims. In the decision under appeal the examining division held that the subject-matter of claims 1 to 13 of this third auxiliary request fulfilled the requirements of Articles 123(2), 84 and 54 EPC, but considered that claim 1 did not fulfil the requirements of Article 56 EPC. Hence, in its decision the examining division has considered neither the requirements of Article 56 EPC in relation to the other claims, in particular the independent claims 10 and 13, nor those of Article 83 EPC.

2. In the board's view (see below), the examining division's reasoning in finding that the subject-matter of claim 1 lacks an inventive step is not persuasive and that therefore the decision under appeal is to be set aside.

3. The board has considered remitting the case to the examining division for examination of the remaining issues, but for reasons of procedural economy has decided to deal with the case itself in accordance with Article 111(1) EPC, last half sentence. Therefore, in the following the patentability requirements of all claims are assessed.

Amendments, clarity, support and novelty - Articles 123(2), 84 and 54 EPC

4. In agreement with the examining division's reasoning and decision, the board considers that the subject-matter of claims 1 to 13 fulfils the requirements of Articles 123(2), 84 and 54 EPC.

Sufficiency of disclosure - Article 83 EPC

5. Detoxified pneumolysin (Ply) and poly-histidine triad protein D (PhtD) were known from the prior art at the priority date of the present application (see page 5, line 4 and page 7, lines 1 to 3 of the application as filed). Hence, in the board's view the skilled person is able to make the immunogenic composition of claim 1 or the vaccine of claim 10 on the basis of the disclosure provided in the application. This applies also to the subject-matter of dependent claims 2 to 9, the second medical use of the vaccine according to claims 11 and 12 and the method of making the vaccine according to claim 13.

6. With regard to the second medical use of claims 11 and 12, it is established case law that the application must also disclose the suitability of the product to be manufactured for the claimed therapeutic effect (see Case Law of the Boards of Appeal, 7th edition, II.C.6.2, first paragraph). In the present case the claimed therapeutic effect is the treatment of pneumonia in adults over 55 years of age (claim 11) and the treatment of otitis media in infants (claim 12).

7. The application provides in example 2, and in particular in table 1 on page 22 and figures 1 to 6, serological data disclosing an anti-Ply and anti-PhtD specific immune response in adults above 55 years and in infants following a natural exposure to

S. pneumoniae. Hence, the teaching in the present application alone and, in particular, when considered in the light of the teachings in the prior art documents (D1) and (D2) (see observations in point 15 below) discloses the suitability of the vaccine comprising at least detoxified Ply and PhtD for the therapeutic effects referred to in claims 11 and 12.

8. Thus, the subject-matter of claims 1 to 13 fulfils the requirements of Article 83 EPC.

Inventive step - Article 56 EPC

Closest prior art

9. In assessing whether or not a claimed invention meets the requirements of Article 56 EPC, the Boards of Appeal of the EPO normally apply the "problem-solution" approach, and so will this board in the present case. It requires as a first step the identification of the closest prior art.

The closest prior art is generally a document disclosing subject-matter conceived for the same purpose or aiming at the same objective as the claimed invention and having the most technical features in common, i.e. requiring the minimum of structural modifications (see Case Law of the Boards of Appeal, 7th edition 2013, I.D.3.1).

10. The application is concerned with protein-based compositions useful for the protection against a

S. pneumoniae infection.

Claims 1 and 10

11. The board agrees with the examining division and the appellant that document (D1) is the closest prior art for the subject-matter of claim 1, and also for the subject-matter of claim 10, because it aims at the provision of immunogenic pneumococcal protein combinations for the preparation of a S. pneumoniae vaccine. Moreover, some of the immunogenic compositions disclosed in this document comprise detoxified Ply (named PdB in document (D1), see abstract) including a combination of Ply and pneumococcal surface protein A (PspA) as the preferred vaccine candidate (see page 3032, column 1, second paragraph). The board considers that this combination is the closest prior art.

Problem to be solved and solution

12. According to established case law, for the purposes of the problem-solution approach the problem to be solved is formulated in view of the closest prior art on the one hand, and the claimed invention and the effects achieved by it on the other (see Case Law of the Boards of Appeal, 7th edition 2013, I.D.4.1).

The problem to be solved according to the application is the provision of an immunogenic composition and a vaccine improved over a vaccine comprising unconjugated or conjugated pneumococcal polysaccharides (see page 2, lines 1 to 17 of the application as filed).

The appellant formulates the problem to be solved as the provision of a further combination of S. pneumoniae proteins with improved immunogenicity.

However, since the combination of detoxified Ply and PspA of document (D1) is the closest prior art and since there is no evidence either in the application or in any other document available in these proceedings that the claimed composition is superior to the closest prior art composition, the problem to be solved is to be reformulated as the provision of an alternative composition useful for protection against a

S. pneumoniae infection.

The claimed solution to this problem is the immunogenic composition according to claim 1 and the vaccine according to claim 10, both comprising at least detoxified Ply and PhtD.

13. It is established case law that the assessment of inventive step using the problem-solution approach requires the consideration of whether or not the claimed subject-matter can be regarded as a credible solution to the problem posed. This has to be derivable either from the disclosure of the application as filed and/or from the common general knowledge available at the relevant date (see Case Law of the Boards of Appeal, 7th edition 2013, I.D.4.6). In the present case, whether or not the claimed solution can be considered to credibly solve the problem formulated above was an issue. It has been dealt with in the decision under appeal in the context of the admissibility of the "supplementary technical information" (see section III(i) above).

14. The application discloses, in particular in table 1 on page 22 and figures 1 to 6, the consistent presence of high amounts of anti-Ply and anti-PhtD antibodies in humans previously exposed to S. pneumoniae.

15. As concerns common general knowledge, document (D1) discloses that three different immunogenic pneumococcal protein compositions comprising detoxified Ply are all immunogenic (see table 1 on page 3029). Moreover, these three compositions comprising detoxified Ply significantly protect mice in five out of six challenging experiments with two different pneumococcal strains when compared to a placebo group (see page 3029, column 2, lines 30 to 32; table 2 and figures 2A and 2B on page 3030; page 3031, column 1, lines 18 to 22). Document (D2) discloses the induction of a protective immune response in mice upon the administration of PhtD alone (see example 6).

Thus, the application discloses a consistent and strong antibody response against native PhtD and Ply in humans and the prior art discloses that compositions comprising detoxified Ply are immunogenic. Moreover, the large majority of these compositions and PhtD are known to induce a protective immune response.

16. The board considers that this evidence from the application and the prior art is sufficient to indicate the immunogenic character of the claimed composition and also its usefulness as a vaccine candidate, and thus that the subject-matter of claims 1 and 10 can be considered to credibly solve the problem formulated above. According to established case law, absolute proof, i.e. certainty that a problem has been solved, is not required for establishing that a claimed solution is credible (see for example decision T 716/08 of 19 August 2010, point 16 of the reasons).

17. Hence, the board's conclusion on this issue differs from that of the examining division (see section III(i) above). As a consequence, the board, in contrast to the examining division, takes the post-published technical data (document D6) into account. The data of document (D6) confirm that an immunogenic composition of detoxified Ply and PhtD does indeed have a protective effect and they thus demonstrate its suitability as a vaccine.

18. The essential reason for the examining division's view that the vaccine of claim 10 could not be considered a credible solution to the problem appeared to be the disclosure in document (D1) of the failure of a Ply-comprising composition to induce a protective effect in one out of six challenging experiments.

19. The board observes that despite this single failure the authors of document (D1) summarise their data as "encouraging" and as justifying a "serious consideration of the combination vaccine approach for combating infections caused by S. pneumoniae" (see page 3032, column 1, second paragraph). In view of these statements in document (D1) the board is not convinced by the examining division's view.

Obviousness

20. The question in the present case is whether or not the skilled person, faced with the problem of providing an alternative composition useful for protection against a S. pneumoniae infection, would have modified the closest prior art composition of document (D1) by combining Ply with PhtD instead with PspA.

21. Document (D1) discloses that, of the combinations disclosed in this document, especially the combination of Ply and PspA should be studied in other model systems (see page 3032, column 1, second paragraph). The document also discloses that "further studies would necessarily include an assessment of the protective efficacies of combinations including other recently characterized virulence-associated proteins of

S. pneumoniae such as CbpA" (see page 3032, column 2, lines 1 to 4). It is moreover derivable from document (D1) that PspA is more immunogenic than Ply (see

table 1 on page 3029). In the board's view the skilled person would therefore rather be motivated to include PspA - and not Ply - in a composition and combine it with other virulence factors when looking for an alternative composition useful for protection against a S. pneumoniae infection. Thus, the claimed combination which comprises Ply cannot be considered as obvious in the light of the teaching of document (D1) alone.

22. Assuming that the skilled person had considered retaining Ply instead of PspA in the combination, the question is whether or not the skilled person would have been motivated to replace PspA by PhtD.

Document (D1) deals with protein-based vaccine compositions containing exclusively virulence-associated factors of this microorganism (see the references in point 21 above). PhtD is neither mentioned in this document nor is its involvement in the virulence of S. pneumonia derivable from it.

In fact, there is evidence suggesting that PhtD is not considered as a virulence factor. Document (D5) discloses that S. pneumoniae has eight different virulence factors, inter alia those disclosed in document (D1) (see figure 1). PhtD is not among those listed.

Document (D2) discloses four pneumococcal Pht proteins, inter alia PhtD. This document too neither discloses nor suggests that PhtD is a pneumococcal virulence factor.

Thus, in contrast to the decision under appeal, the board comes to the conclusion that the skilled person would not be motivated by the teachings of documents (D1) and (D2) to replace PspA by PhtD because the skilled person would not have considered PhtD to be a virulence factor. Thus, also for this reason the claimed combination is not considered as obvious.

23. With regard to the subject-matter of claim 1, the examining division declined to acknowledge an inventive step (see section III(ii) above). It formulated the problem to be solved as the provision of an alternative immunogenic composition. The examining division considered that in relation to this problem the combination of Ply and PhtD was the result of "an arbitrary selection among the solutions that can be generated on the basis of the disclosure of the antigenic proteins of both D1 and D2. Such an arbitrary selection, however, fails to represent a contribution to the prior art for which an inventive step can be acknowledged". To support its view the examining division referred to decisions T 939/92 of

12 September 1995, T 964/92 of 23 August 1994 and

T 350/95 of 23 July 1998.

24. The situation as described by the examining division in its decision is the one which is also derivable from the reasoning of all three decisions cited by it, i.e. claimed subject-matter is considered as obvious because it constitutes a choice from a larger number of alternatives, all of which the skilled person would have considered as equally suitable to solve a formulated technical problem and where the chosen compounds are not characterised by another, unexpected effect. Such a choice is denoted in the case law as "arbitrary".

25. In decision T 939/92, supra, the board, following the appellant's argumentation, formulated a "hypothetical" technical problem as the "provision of further (or alternative) chemical compounds, regardless of their likely useful properties". The board considered that "all structurally similar chemical compounds, irrespective of their number, that a skilled person would expect, in the light of the prior art, to be capable of being synthesised, are equally suitable candidates for solving such a hypothetical "technical problem", and would therefore all be equally "suggested" to the skilled person. It follows from these considerations that a mere arbitrary choice from this host of possible solutions of such a "technical problem" cannot involve an inventive step" (see points 2.5 and 2.5.3 of the reasons).

26. In decision T 964/92, supra, the problem to be solved was formulated as "providing further compounds having activity against angina pectoris". The appellant argued inter alia that "the skilled person would have had to consider a host of possible alternatives" as a solution to this problem, and that "in the absence of any hint in the prior art towards the suitability of the relative small group of compounds defined in the present Claim 1, the selection of this group was not obvious, since the skilled person would not have chosen just this group." The board dismissed this argument by stating that "if, as in the present case, a number of modifications was obvious, all compounds resulting from such modifications, irrespective of their number, are equally suitable candidates for solving that technical problem and would therefore all be "suggested" to the skilled person. Any arbitrary choice among them does therefore not involve an inventive step" (see points 2.8 to 2.10 of the reasons).

27. In decision T 350/95, supra, the problem to be solved was the "provision of a further hydrocracking process". The board found that by following the teaching in document D1 "the skilled person would have obtained stabilised zeolites having unit cell sizes lying with a range which overlaps with the range specified in present claim 1. Furthermore, the stabilised zeolites of D1 are said to be suitable for use in catalyst compositions for hydrocracking operations". Under these circumstances the board considered that the claimed solution to the problem, constitutes "no more than an arbitrary choice from the broad class of stabilised zeolites made available by D1" (see points 4.2 and 4.3 of the reasons).

28. In the present case, document (D1) indicates that not all combinations containing Ply are equally immunogenic (see table 1 on page 3029). Moreover, the document points to possible "antagonistic" effects between the proteins, influencing their immunogenicity when used in combination (see page 3029, column 1, third paragraph). Hence, in contrast to the circumstances underlying the cited decisions, in the present case the skilled person would not perceive that all of the possibly suggested combinations are equally immunogenic. Therefore, in the light of the concept developed by the case law (see point 24 above), the choice of the particular combination claimed cannot be considered to be the result of an "arbitrary" choice. Thus, the examining division's view is not persuasive.

29. In summary, the board concludes that the immunogenic composition according to claim 1 and the vaccine according to claim 10, both comprising at least detoxified Ply and PhtD, involve an inventive step (Article 56 EPC). This conclusion also applies to the subject-matter of dependent claims 2 to 9, to the subject-matter of claims 11 and 12 relating to a second medical use of the vaccine according to claim 10, and to the subject-matter of claim 13 relating to a method for producing the vaccine of claim 10.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to grant a patent on the basis of auxiliary request 1 filed with the statement of grounds of appeal and a description and figures to be adapted thereto.

| |

|

| |

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility